General：abirateron Acetate (CB7630) is the acetate form of abirateron, a steroid cytochrome CYP17 inhibitor with an IC50 of 72 nM in cell-free assays. Acetic acid abirateron is an orally effective CYP17 inhibitor that is metabolized into abirateron and exerts its effects in the body.

Function：Abitherone acetate is a CYP17 inhibitor that can be used in combination with * to treat prostate cancer patients. Acetic acid abirateron is a prodrug that can be converted into abirateron upon entry into the body. The latter is an inhibitor of androgen biosynthesis that exerts therapeutic effects by inhibiting the activity of CYP17 enzyme, thereby inhibiting androgen biosynthesis.

Origin：Acetate Abitherone was initially developed in collaboration with the UK Cancer Institute and BTG, and later transferred global development and listing rights to Cougar Biopharmaceutical Company (now a subsidiary of Johnson&Johnson) in the United States. Abitherone acetate was first approved for sale in the United States on April 28, 2011.